OVERVIEW

23rd Pharmacovigilance 2020 is organized by Virtue Insight and will be held on Dec 16, 2020.

Description:
Brings together top pharmaceutical, biotechnology ad regulatory representatives under one roof.

Virtue insight’s 23rd Pharmacovigilance Conference is more than a traditional conference. It is a unique opportunity to learn about the latest trends, to engage with renowned experts, and to personally develop as a healthcare professional. The 23rd Pharmacovigilance Conference will take place virtually for the very first time on 16th December 2020

This conference provides the foundation for strong strategic planning and practical decision-making in your pharmacovigilance programs. This year’s conference will address the current thinking on predicting and assessing risks such as drug-induced liver injury, and the assessment of expectedness of serious adverse reactions during clinical development. The complexities of assessing benefit-risk balance of today’s therapies, including immunotherapy and other advanced therapies, will be examined. Experts will present approaches and engage in dialogs around more extensive and impactful uses of real world data and generation of RWE for safety assessments. A full-day will be devoted to the development, implementation, and assessment of risk management strategies for drugs approved in multiple regions

Take the opportunity to learn from regulators and leading experts and discover what the challenges and opportunities will be in the field of Pharmacovigilance in 2020.

Do not miss out on these exciting discussions. Join us virtually to discover and learn from the experts who will be joining us on 16th December 2020.

We look forward to seeing you there!

Key Themes Discussed:
• Review, predictions & updates on the global pharmacovigilance market
• Key regulations and pharmacovigilance system
• Pharmacovigilance and its importance in the pharmaceutical industry expands
• Discussion of pharmacovigilance and its effect in healthcare and patient care
• Demand for pharmacovigilance and consumer research
• Addressing concerns with drug safety by recognizing the risks associated with pharmaceutical products and reducing the possibility of any potential harm to patients
• Present legislation and proposals for pharmaceutical drugs endorse and carry out post marketing drug tests
• Planning pharmacovigilance and risk management
• Concentrating on the pharmacovigilance regulatory system in the form of risk management planning
• A performance risk management strategy across the drug development lifecycle
• The complexities of communicating and controlling the established quality risks
• Addressing global perspective of pharmacovigilance and risk management strategies
• Discussing about improving health outcomes and patient safety
• Real world evidence: The evolving regulatory landscape, information and integrated usage
• How real-world data is used today to produce evidence in major markets
• A new approach and support towards pharmacovigilance regulations
• New regulatory guidelines and laws governing pharmacovigilance
• Be part of a major networking opportunity